G1 Therapeutics (GTHX +4.6%) has announced a license agreement with Simcere Pharmaceutical, for the development and commercialization of trilaciclib across all indications in Greater China, including mainland China, Hong Kong, Macau and Taiwan.
Under the terms of the agreement, G1 will receive an upfront payment of $14M, and be eligible to receive up to $156M in milestone payments, as well as tiered low double-digit sales-based royalties.
Trilaciclib is a first-in-class myelopreservation agent designed to protect the bone marrow from damage by chemotherapy.
https://seekingalpha.com/news/3599181-g1-therapeutics-inks-trilaciclib-pact-simcere-in-greater-china
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.